Please select your view


Blood Cancer

BCR-ABL Molecular Genetic Testing

Alongside our comprehensive molecular oncology and haematology service, Australian Clinical Labs is offers both qualitative and quantitative BCR-ABL molecular genetic testing for haematological malignancies. Detection of the BCR-ABL fusion genes has diagnostic and therapeutic implications in chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL).

The test is NATA/RCPA accredited and will be performed using a highly-sensitive quantitative PCR assay (ddPCR) at our Molecular Genetics Centre of Excellence in Melbourne, Victoria.

With BCR-ABL testing performed in-house at Clinical Labs, your patient results will be provided in the same convenient method as your other Clinical Labs results, and will be provided with a quicker turnaround time than previously. There is no change in test fee – with the BCR-ABL test able to be covered by Medicare for all eligible cases.

About the BCR-ABL gene fusion

The BCR-ABL gene fusion is acquired when pieces of chromosome 9 and chromosome 22 break off and switch places. The resulting chromosome 22 that has the BCR-ABL gene sequence is known as the Philadelphia chromosome. The BCR-ABL gene encodes an abnormal protein that is responsible for the development of CML and a type of ALL. This abnormal protein drives uncontrolled growth of leukemic cells. At diagnosis, 90-95% of cases of CML show the characteristic t(9;22) BCR-ABL reciprocal chromosomal translocation.




The content on our Molecular Cancer Services page is written by Associate Professor Mirette Saad, National Director of Molecular Genetics at Australian Clinical Labs. 


Assoc. Prof. Mirette Saad

Lab: Clayton
Speciality: Chemical Pathology and Molecular Genetics
Areas Of Interest: Cancer Genetics, Antenatal Screening, NIPT, Endocrine, Fertility Testing and Research, Medical Teaching
Phone: 1300 134 111
Email: mirette.saad@clinicallabs.com.au

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer.

Back to Molecular Cancer Services Homepage